Frasier and Denys-Drash syndromes: Different disorders or part of a spectrum?

Archives of Disease in Childhood

Volumn 81, Issue 4, 1999, Pages 365-369

  Koziell, Ania ^a   Grundy, Richard ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DENYS DRASH SYNDROME; DISEASE CLASSIFICATION; FRASIER SYNDROME; GENE ISOLATION; GENE MUTATION; HUMAN; OVARY DEVELOPMENT; PRIORITY JOURNAL; REVIEW;

EID: 0032835981     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.81.4.365     Document Type: Review

References (41)

1. Denys P, Malvaux P, van den Berghe H, Tanghe W, Proemans W. Association d'un syndrome anatomopathologique de pseudo-hermaphrodisine masculin, d'un tumeur de Wilms' d'un nephropathie parenchymarteuse et d'un mosaicisme XX/XY. Arch Fr Pediatr 1967;24:729-39.
2. Drash A, Sherman F, Harmann W, Blizzard R. A syndrome of pseudohermaphroditism, Wilms' tumour, hypertension and degenerative renal disease. J Paediatr 1970;76:585-93.
3. Eddy AA, Mauer SM. Pseudohermaphroditisim, glomerulopathy, and Wilms' tumor (Drash syndrome): Frequency in end-stage renal failure. J Pediatr 1985;106:584-7.
4. Bardeesy N, Zabel B, Schmitt K, Pelletier J. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion - brief report. Genomics 1994;21:663-5.
5. Coppes MJ, Campbell CE, Williams BRG. The role or WT1 in Wilms' tumorigenesis. FASEB J 1993;7:886-95.
6. Mueller RF. The Denys-Drash syndrome. J Med Genet 1994;31:471-7.
7. Knudson AG, Jr, Strong LC. Mutation and cancer; a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972;48:313-24.
8. Coppes MJ, DeKraker J, van Dijken PL et al. Bilateral Wilms' tumour, long term survival and some epidemiological features. J Clin Oncol 1989;7:310-15.
9. Montgomery B, Kelais P, Blute M, et al. Extended follow up of bilateral Wilms' tumour; results of the national Wilms' tumour study. J Urol 1991;146:514-18.
10. Breslow N, Beckwith J, Ciol M, Sharples K. Age distribution of Wilms' tumour: report from the national Wilms' tumour study group. Cancer Res 1988;48:1653-7.
11. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol 1990; 10:1-36.
12. Beckwith JB. Precursor lesions of Wilms' tumor: clinical and biological implications. Med Pediatr Oncol 1993;21:158-68.
13. Frasier SD, Bashore RA, Mosier HD. Gonadoblastoma associated with pure gonadal dysgenesis in monozygotic twins. J Pediatr 1964;64:740-5.
14. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
15. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990;343:774-8.
16. Francke U, Holmes LB, Atkins L, Riccardi VM. Aniridia-Wilms' tumor association: evidence for specific deletion of 11p13. Cytogenet Cell Genet 1979;24:185-92.
17. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990;346:194-7.
18. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie NP, Bard JB. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 1992;40:85-97.
19. Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell 1993;74:679-91.
20. Rauscher FJ. The WT1 Wilms' tumor gene product - a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. EASEB J 1993;7:896-903.
21. Larsson SH, Charlieu JP, Miyagawa K, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995;81:391-401.
22. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms' tumor gene WT1. Proc Natl Acad Sci USA 1991;88:9618-22.
23. Morris JF, Madden SL, Tournay OE, Cook DM, Sukhatme VP, Rauscher FJ. 3d Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus. Oncogene 1991;6:2339-4.
24. Bruening W, Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. J Biol Chem 1996;271:8646-54.
25. Jeanpierre C, Beroud C, Niaudet P, Junien C. Software and database for the analysis of mutations in the human WT1 gene. Nucleic Acids Res 1998;26:271-4.
26. Little MH, Williamson KA, Mannens M, et al. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum Mol Genet 1993;2:259-64.
27. Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet 1995;4:351-8.
28. Borel F, Barilla KC, Hamilton TB, Iskandar M, Rumaniuk PJ. Effect of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1. Biochemistry 1996;35:12070-6.
29. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209-25.
30. Moffett P, Bruening W, Nakagama H, et al. Antagonism of WT1 activity by protein self-association. Proc Natl Acad Sci 1995;92:11105-9.
31. Nachtigal MW, Hirokawa Y, Enycart-VanHouten DL, Flanagan JN, Hammer GD, Ingraham HA. Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998:93:445-54.
32. Gessler M, König A, Arden K, et al. Infrequent mutation of the WT1 gene in 77 Wilms' tumors. Hum Mutat 1994;3:212-22.
33. Varanasi R, Bardeesy N, Ghahremani M, et al. Fine structure analysis of the WT1 gene hi sporadic Wilms' tumors. Proc Natl Acad Sci USA 1994;91:3554-8.
34. Brown KW, Wilmore HP, Watson JE, Mott MG, Berry PJ, Maitland NJ. Low frequency of mutation in the WT1 coding region in Wilms' tumor. Genes Chromosomes Cancer 1993;8;74-9.
35. Barbaux S, Niaudet P, Gubler MC, et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997;17; 167-70.
36. Kichuchi H, Takata A, Akasaka Y, et al. Do intronic mutations affecting splicing of WT1 exon 9 cause Frasier syndrome? J Med Genet 1998;35:15-8.
37. Klamt B, Koziell AB, Poulat F, et al. Frasier syndrome is caused by defective alternative splicing leading to an altered ratio of WT1 +/- KTS splice isoforms. Hum Mol Genet 1998;74:709-714
38. McMaster ML, Gessler M, Stanbridge EJ, Weissman BE. WT1 expression alters tumorigenicity of the G401 kidney-derived cell line. Cell Growth Differ 1995;6:1609-17.
39. Jeanpierre C, Denamur E, Henry I, et al. Identification of constitutional WT1 mutations in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/ phenotype correlations by use of a computerized mutation database. Am J Hum Genet 1998;62:824-33.
40. Schumacher V, Scharer K, Wuhl E, et al. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney Int 1998:53:1594-1.
41. Martinot I., Denamur E, Mougenot BP, Bensman RA. Mutation of WT1 gene in a family with Denys-Drash and focal segmental sclerosis [abstract] Abstracts in Paediatric Nephrology 1998;12:C88.